Gilead Sciences, Inc.
Foster City, CA 4 processed 13Fs on this site, 2025 Q3 to 2026 Q2
- $1.6B
- 5 holdings
- 2026 Q2
- −22.1% QoQ
- Top 5 100.0%
AUM over time
Book
| RCUS, Arcus Biosciences | Hold | 31,424,760 | $23.83 | $749M | — | — | |
| LKFT, Galapagos | Hold | 16,707,477 | $32.96 | $551M | — | — | |
| ACLX, Arcellx | Hold | 6,720,803 | $65.20 | $438M | — | — | |
| ASMB, Assembly Biosciences | Hold | 4,505,391 | $34.01 | $153M | — | — | |
| Kyverna Therapeutics | Hold | 4,126,119 | $9.40 | $39M | — | — | |
| Xilio Therapeutics | Hold | 9,105,451 | $0.6402 | $5.8M | — | — |
Exits / last held
Gone since 2025 Q3, shown at their last reported size.
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Merus | Exit | 0 | $94.15 | $43M | −452,527 | −$43M | |
| TNGX, Tango Therapeutics | Exit | 0 | $8.40 | $41M | −4,854,443 | −$41M | |
| Leap Therapeutics | Exit | 0 | $0.4540 | $2.4M | −5,319,148 | −$2.4M |
Filings history
4 periods, with AUM normalized
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 5 | $1.6B | −22.1% | 13F-HR | 8/3/2026 | 000112329226001034 |
| 2026 Q1 | 6 | $2.1B | +9.4% | 13F-HR | 5/8/2026 | 000112329226000642 |
| 2025 Q4 | 6 | $1.9B | +8.1% | 13F-HR | 2/12/2026 | 000112329226000164 |
| 2025 Q3 | 9 | $1.8B | — | 13F-HR | 11/13/2025 | 000112329225000642 |
About
Gilead Sciences, Inc.
4 processed 13Fs on this site, 2025 Q3 to 2026 Q2
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
- One Up On Wall Street (Lynch), Peter Lynch View on Amazon